445 related articles for article (PubMed ID: 24139235)
1. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.
Ploussard G; Shariat SF; Dragomir A; Kluth LA; Xylinas E; Masson-Lecomte A; Rieken M; Rink M; Matsumoto K; Kikuchi E; Klatte T; Boorjian SA; Lotan Y; Roghmann F; Fairey AS; Fradet Y; Black PC; Rendon R; Izawa J; Kassouf W
Eur Urol; 2014 Aug; 66(2):361-70. PubMed ID: 24139235
[TBL] [Abstract][Full Text] [Related]
2. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
[TBL] [Abstract][Full Text] [Related]
3. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
5. Robot-assisted radical cystectomy: description of an evolved approach to radical cystectomy.
Collins JW; Tyritzis S; Nyberg T; Schumacher M; Laurin O; Khazaeli D; Adding C; Jonsson MN; Hosseini A; Wiklund NP
Eur Urol; 2013 Oct; 64(4):654-63. PubMed ID: 23769588
[TBL] [Abstract][Full Text] [Related]
6. Conditional survival after radical nephroureterectomy for upper tract carcinoma.
Ploussard G; Xylinas E; Lotan Y; Novara G; Margulis V; Rouprêt M; Matsumoto K; Karakiewicz PI; Montorsi F; Remzi M; Seitz C; Scherr DS; Kapoor A; Fairey AS; Rendon R; Izawa J; Black PC; Lacombe L; Shariat SF; Kassouf W
Eur Urol; 2015 Apr; 67(4):803-12. PubMed ID: 25145551
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma.
Fritsche HM; May M; Denzinger S; Otto W; Siegert S; Giedl C; Giedl J; Eder F; Agaimy A; Novotny V; Wirth M; Stief C; Brookman-May S; Hofstädter F; Gierth M; Aziz A; Kocot A; Riedmiller H; Bastian PJ; Toma M; Wieland WF; Hartmann A; Burger M
Eur Urol; 2013 Apr; 63(4):739-44. PubMed ID: 23079053
[TBL] [Abstract][Full Text] [Related]
9. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
Rink M; Zabor EC; Furberg H; Xylinas E; Ehdaie B; Novara G; Babjuk M; Pycha A; Lotan Y; Trinh QD; Chun FK; Lee RK; Karakiewicz PI; Fisch M; Robinson BD; Scherr DS; Shariat SF
Eur Urol; 2013 Sep; 64(3):456-64. PubMed ID: 23206854
[TBL] [Abstract][Full Text] [Related]
10. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
12. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
13. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.
Kassouf W; Spiess PE; Brown GA; Munsell MF; Grossman HB; Siefker-Radtke A; Dinney CP; Kamat AM
Eur Urol; 2007 Sep; 52(3):769-74. PubMed ID: 17434254
[TBL] [Abstract][Full Text] [Related]
14. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database.
Fairey AS; Jacobsen NE; Chetner MP; Mador DR; Metcalfe JB; Moore RB; Rourke KF; Todd GT; Venner PM; Voaklander DC; Estey EP
J Urol; 2009 Jul; 182(1):85-92; discussion 93. PubMed ID: 19447413
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
Kang M; Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
Sci Rep; 2015 Jul; 5():12171. PubMed ID: 26212449
[TBL] [Abstract][Full Text] [Related]
16. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy.
Simone G; Papalia R; Ferriero M; Guaglianone S; Castelli E; Collura D; Muto G; Gallucci M
Int J Urol; 2013 Apr; 20(4):390-7. PubMed ID: 22970939
[TBL] [Abstract][Full Text] [Related]
17. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
19. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
Briganti A; Karnes RJ; Da Pozzo LF; Cozzarini C; Capitanio U; Gallina A; Suardi N; Bianchi M; Tutolo M; Salonia A; Di Muzio N; Rigatti P; Montorsi F; Blute M
Eur Urol; 2011 May; 59(5):832-40. PubMed ID: 21354694
[TBL] [Abstract][Full Text] [Related]
20. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy.
May M; Herrmann E; Bolenz C; Brookman-May S; Tiemann A; Moritz R; Fritsche HM; Burger M; Trojan L; Michel MS; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Gilfrich C; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Bastian PJ
Ann Surg Oncol; 2011 Jul; 18(7):2018-25. PubMed ID: 21246405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
